Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial.

Akinori HaraMiho ShimizuErika HamaguchiHirokazu KakudaKenzo IkedaToshiya OkumuraKiyoki KitagawaYoshitaka KoshinoMotoo KobayashiKazuya TakasawaYukimasa HisadaTadashi ToyamaYasunori IwataNorihiko SakaiTakashi Wada

Published in: Endocrinology, diabetes & metabolism (2020)

Although the treatment with PG was generally well tolerated, the dosage of 30 mg/d for 12 months did not reduce albuminuria when used in addition to usual care in patients with type 2 diabetes and nephropathy. Efficacy of PG should be verified in future definitive trials.

Keyphrases

healthcare
palliative care
quality improvement
current status
squamous cell carcinoma
locally advanced
pain management
smoking cessation